β‐Estradiol results in a proprotein convertase subtilisin/kexin type 9‐dependent increase in low‐density lipoprotein receptor levels in human hepatic HuH7 cells
Open Access
- 18 May 2015
- journal article
- Published by Wiley in The FEBS Journal
- Vol. 282 (14) , 2682-2696
Abstract
The lower risk of coronary artery disease in premenopausal women than in men and postmenopausal women implicates sex steroids in cardioprotective processes. β‐Estradiol upregulates liver low‐density lipoprotein receptor (LDLR), which, in turn, decreases circulating levels of low‐density lipoprotein, which is a risk factor for coronary artery disease. Conversely, LDLR protein is negatively regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we investigated PCSK9 regulation by β‐estradiol and its impact on LDLR in human hepatocarcinoma HuH7 cells grown in the presence or absence of β‐estradiol. Immunoblot analysis showed upregulation of LDLR at 3 μm β‐estradiol (140%), and the upregulation reached 220% at 10 μm β‐estradiol; only at the latter dose was an increase in LDLR mRNA detected by qPCR, suggesting post‐translational regulation of LDLR. No changes in PCSK9 mRNA or secreted protein levels were detected by qPCR or ELISA, respectively. β‐estradiol‐conditioned medium devoid of PCSK9 failed to upregulate LDLR. Similarly, PCSK9 knockdown cells showed no upregulation of LDLR by β‐estradiol. Together, these results indicate a requirement for PCSK9 in the β‐estradiol‐induced upregulation of LDLR. A radiolabeling assay showed a significant, dose‐dependent decrease in the ratio of secreted phosphoPCSK9 to total secreted PCSK9 with increasing β‐estradiol levels, suggesting a change in the functional state of PCSK9 in the presence of β‐estradiol. Our results indicate that the protein upregulation of LDLR at subtranscriptionally effective doses of β‐estradiol, and its supratranscriptional upregulation at 10 μm β‐estradiol, occur through an extracellular PCSK9‐dependent mechanism.Keywords
Funding Information
- Canadian Institutes of Health Research
- The Richard and Edith Strauss Foundation
This publication has 53 references indexed in Scilit:
- Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expressionInternational Journal of Molecular Medicine, 2010
- Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expressionBiochemical and Biophysical Research Communications, 2010
- LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL ReceptorScience, 2009
- PCSK9 is phosphorylated by a Golgi casein kinase‐like kinase ex vivo and circulates as a phosphoprotein in humansThe FEBS Journal, 2008
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivoBiochemical and Biophysical Research Communications, 2008
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJournal of Clinical Investigation, 2006
- Neuroendocrine Protein 7B2 Can Be Inactivated by Phosphorylation within the Secretory PathwayJournal of Biological Chemistry, 2006
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Estrogen receptor-α and Sp1 interact in the induction of the low density lipoprotein-receptorThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Biphasic Effects of the Natural Estrogen 17β-Estradiol on Hepatic Cholesterol Metabolism in Intact Female RatsArteriosclerosis, Thrombosis, and Vascular Biology, 2000